Statement Of Cash Flows [Abstract]

Zealand Pharma - Filing #1440145

Concept As at
2020-12-31
2020-01-01 to
2020-12-31
2019-01-01 to
2019-12-31
As at
2019-12-31
As at
2018-12-31
2018-01-01 to
2018-12-31
As at
2017-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Income taxes paid (refund), classified as operating activities
0 DKK
93,000 DKK
39,500,000 DKK
Cash flows from (used in) operating activities
688,716,000 DKK
409,455,000 DKK
461,420,000 DKK
Cash flows from (used in) investing activities [abstract]
Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities
167,791,000 DKK
0 DKK
0 DKK
Proceeds from sales of property, plant and equipment, classified as investing activities
0 DKK
25,000 DKK
0 DKK
Purchase of property, plant and equipment, classified as investing activities
25,044,000 DKK
21,036,000 DKK
4,038,000 DKK
Purchase of intangible assets, classified as investing activities
0 DKK
2,480,000 DKK
0 DKK
Dividends received, classified as investing activities
0 DKK
878,000 DKK
1,020,000 DKK
Cash flows from (used in) investing activities
196,807,000 DKK
51,666,000 DKK
882,925,000 DKK
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
791,503,000 DKK
645,145,000 DKK
0 DKK
Payments of lease liabilities, classified as financing activities
29,219,000 DKK
8,689,000 DKK
158,311,000 DKK
Cash flows from (used in) financing activities
760,941,000 DKK
674,480,000 DKK
155,449,000 DKK
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
124,582,000 DKK
213,359,000 DKK
266,056,000 DKK
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
3,743,000 DKK
7,066,000 DKK
5,861,000 DKK
Cash and cash equivalents
960,221,000 DKK
1,081,060,000 DKK
860,635,000 DKK
588,718,000 DKK

Talk to a Data Expert

Have a question? We'll get back to you promptly.